Skip to content
TrialScanner

NCT04844749

Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Phase 3TerminatedVERULead

Registry record

Lead sponsor
Veru Inc.
Conditions
Metastatic Castration-resistant Prostate Cancer; Androgen Resistant Prostatic Cancer
Primary completion
May 4, 2023Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04844749 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04844749: Efficacy Evaluation of... | TrialScanner